Skip to main content

Table 3 Frequency of two MC subsets in human diseases

From: Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases

Disease CD14 ++CD16 -(classical, phagocytic) CD14 +CD16 +(Non-classical, inflammatory) Functional changes associated with CD14 ++CD16 +MC expansion PMID #
Rheumatoid Arthritis No change 2.2% ↑ HLA-DR and CCR5↑ Counts of tender/swollen joints↑ Rheumatoid factors ↑ 12384915
CAD   2.2% ↑ Serum TNFα ↑ 15269840
CAD   8%  ↑ Plaque vulnerability↑ 20684824
Atherosclerosis 8% ↓ 8%  ↑   19461894
Hemophagocytic syndrome   31% ↑ Serum TNFα & IL-6↑ 17619880
Crohn’s disease   5.7% ↑   17260384
Tumor/haematological malignancy   13.3% ↑   10209505
  1. Circulating classical (CD14++CD16-, also described as CD14brightCD16-, phagocytic) and non-classical (CD14+ CD16+, also described as CD14brightCD16+, inflammatory) MC counts were examined in human disease as indicated. The percentage change of MC subsets and some functional measurements are recorded. We used PMID # to cite individual manuscripts reporting these studies. MC, monocyte; AMI, acute myocardial infarction; CAD, coronary arterial disease; CKD, chronic kidney disease; HLA-DR, human leukocyte antigen DR (MHC-II, major histocompatibility complex class II); TNFα, tumor necrosis factor α; IL-6, interleukin 6; ↑, increase.